76例儿童急性肝衰竭病因及临床转归分析

摘要/Abstract

摘要： 目的分析儿童急性肝衰竭(ALF)的病因和临床转归。方法收集2010年1月—2021年1月期间长江大学附属仙桃市第一人民医院收治ALF患儿76例(男43例、女33例),年龄1个月～12岁。定期随访,依据临床转归结果将患儿分为存活组、死亡组,搜集ALF患儿病因,比较存活组、死亡组临床资料并作多因素分析。结果 76例ALF患儿病因未明确31例(40.8%)、病因明确45例(59.2%)。后者药物源性损害14例(18.4%)、感染性疾病11例(15.8%)、解剖异常(血管或胆道先天发育异常)9例(14.5%)、遗传代谢性疾病7例(9.2%)、自身免疫性疾病3例(3.9%)及肿瘤性疾病1例(1.3%)。76例ALF患儿中存活、死亡分别为44例、32例,比较临床资料可知,存活组ALT、AST[1 108(504, 3 114)U/L、1 226(808, 3 225)U/L]均显著高于死亡组[526(204, 915)U/L、717(470, 1 948)U/L, Z=27.402, 24.153, P<0.05];存活组Alb、TBil、DBil及血氨分别为33.2(30.2, 38.4)g/L、61.2(26.5, 182.4)μmol/L、38.0(12.9, 114.8)μmol/L及80.0(60.5, 101.7)μmol/L,与死亡组[28.7(26.0, 31.4)g/L、152.9(70.6, 288.0)μmol/L、87.6(41.6, 158.2)μmol/L及109.5(85.5, 146.6)μmol/L]相比,差异具有统计学意义(Z=8.162, -30.429, -48.624及-9.489, P<0.05);存活组PT、INR[24.2(21.0, 29.8)s、2.1(1.8, 2.8)]均显著低于死亡组[38.4(24.4, 52.5)s、3.3(2.3, 6.6), Z=-20.197, -21.158, P<0.05];存活组PELD评分[20.2(18.4, 32.0)分]显著高于死亡组[30.8(24.6, 39.0)分,Z=-22.278, P<0.05]。将ALT、AST、Alb、TBil、DBil、血氨、PT、INR及PELD评分作为自变量,ALF患儿临床转归结局作为应变量(赋值0=存活,1=死亡),纳入logistic回归分析,结果提示TBil及PELD评分是ALF患儿临床转归中死亡发生的独立危险因素(P<0.05)。结论儿童ALF病死率高,常见病因包括药物源性损害、感染性疾病、解剖异常(血管或胆道先天发育异常)、遗传代谢性疾病、自身免疫性疾病及肿瘤性疾病。ALF患儿TBil、PELD评分升高提示预后不良。

关键词: 急性肝衰竭, 儿童, 儿童终末期肝病模型评分

Abstract: Objective To investigate the etiology and clinical outcome of 76 children with acute liver failure (ALF). Methods A total of 76 children (43 males and 33 females) with ALF admitted to our hospital from January 2010 to January 2021 were included, with an average age of 1 month to 12 years. All the objects were followed up regularly and death group according to the clinical outcome. The etiology of ALF children were collected, and the clinical data of survival group and death group were compared and analyzed by multiple-factor analysis. Results The etiology of 31 (40.8%) cases was unclear and etiology of 45 (59.2%) cases was definite. Among the latter, 14 cases were drug-induced injury (18.4%), 11 cases were infectious diseases (15.8%), 9 cases were anatomical abnormalities (congenital dysplasia of blood vessels or biliary tract) (14.5%), 7 cases were hereditary metabolic diseases (9.2%), 3 cases were autoimmune diseases (3.9%) and 1 case was neoplastic diseases (1.3%). Among the 76 children with ALF, 44 cases survived and 32 cases died, respectively. Compared with clinical data, the alanine transaminase (ALT) and aspartate aminotransferase (AST) [1108 (504, 3114) U/L and 1226 (808, 3225) U/L] in the survival group were significantly higher than those in the death group [526 (204, 915) U/L and 717 (470,1948) U/L, Z=27.402, 24.153, P<0.05]. In the survival group, the albumin (Alb), total bilirubin (TBil), direct bilirubin (DBil) and blood ammonia of survival group [33.2 (30.2, 38.4) g/L, 61.2 (26.5, 182.4) μmol/L, 38.0 (12.9, 114.8) μmol/L and 80.0 (60.5, 101.7) μmol/L] were significantly different from those in death group [28.7 (26.0, 31.4) g/L、152.9(70.6, 288.0) μmol/L, 87.6 (41.6, 158.2) μmol/L and 109.5 (85.5, 146.6) μmol/L], P<0.05. The survival group plotting time PT and international normalized ratio (INR) were 24.2(21.0, 29.8) s and 2.1(1.8, 2.8), which was significantly different from the death group [38.4(24.4, 52.5) s and 3.3(2.3, 6.6)] (Z=-20.197, -21.158, P<0.05). PELD score of survival group [20.2 (18.4, 32.0) points] was significantly higher than that of death group [30.8 (24.6, 39.0) points, Z=-22.278, P<0.05]. Taking the ALT, AST, Alb, TBil, DBil, blood ammonia, PT, INR and PELD score as independent variables, and the clinical outcome was taken as dependent variable (assigned 0 = survival, 1 = death), and the logistic regression analysis was conducted. The results indicated that TBil and PELD scores were independent risk factors of death in the clinical outcome of children with ALF (P<0.05). Conclusion The mortality of children with ALF is high, and the common causes are drug-induced damage, infectious diseases, anatomical abnormalities (congenital dysplasia of blood vessels or biliary tract), genetic metabolic diseases, autoimmune diseases and neoplastic diseases. The increase of TBil and PELD scores in children with ALF indicates poor prognosis.

Key words: Acute liver failure, Children, Pediatric end-stage liver disease score

金建国, 华晴. 76例儿童急性肝衰竭病因及临床转归分析[J]. 肝脏, 2023, 28(2): 162-164.

JIN Jian-guo, HUA Qing. Analysis on etiology and clinical outcome of 76 children with acute liver failure[J]. Chinese Hepatolgy, 2023, 28(2): 162-164.

参考文献

[1] Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr, 2006, 148(5):652-658.
[2] Jain V, Dhawan A. Prognostic modeling in pediatric acute liver failure. Liver Transpl, 2016, 22(10):1418-1430.
[3] Chien MM, Chang MH, Chang KC, et al. Prognostic parameters of pediatric acute liver failure and the role of plasma exchange. Pediatr Neonatol, 2019, 60(4):389-395.
[4] Mendizabal M, Dip M, Demirdjian E, et al. Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure. Liver Transpl, 2020, 26(2):268-275.
[5] Chapin CA, Horslen SP, Squires JE, et al. Corticosteroid therapy for indeterminate pediatric acute liver failure and aplastic anemia with acute hepatitis. J Pediatr, 2019, 208:23-29.
[6] Wands D, Tayler R, Kelly D, et al. Infantile acute liver failure in the West of Scotland. Arch Dis Child, 2020, 105(8):794-796.
[7] Núñez-Ramos R, Montoro S, Bellusci M, et al. Acute liver failure: outcome and value of pediatric end-stage liver disease score in pediatric cases. Pediatr Emerg Care, 2018, 34(6):409-412.
[8] Yankol Y, Ertugrul M, Kanmaz T, et al. Management of pediatric acute liver failure in a region with insufficient deceased donor support: a single-center experience. Exp Clin Transplant, 2016, 14(5):535-541.
[9] 中华医学会感染病学分会肝衰竭与人工肝学组中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 临床肝胆病杂志, 2019, 35(1):38-44.
[10] Li JQ, Qiu YL, Gong JY, et al. Novel NBAS mutations and fever-related recurrent acute liver failure in Chinese children: a retrospective study. BMC Gastroenterol, 2017, 17(1):77.
[11] Wang DW, Yin YM, Yao YM. Advances in the management of acute liver failure. World J Gastroenterol, 2013, 19(41):7069-7077.
[12] 马威, 孙娟, 王晓玲, 等. 儿童急性肝衰竭的病因构成分析及短期疗效评价. 中华肝脏病杂志, 2020, 28(11): 959-963.
[13] Lee H, Yoon S, Oh SY, et al. Comparison of APACHE IV with APACHE II, SAPS 3, MELD, MELD-Na, and CTP scores in predicting mortality after liver transplantation. Sci Rep, 2017, 7(1):10884.
[14] 王威, 吴霞, 颜炳柱, 等. 血浆置换治疗68例肝衰竭的临床疗效观察. 实用肝脏病杂志, 2010, 13(02):134-136.
[15] Sanchez MC, D'Agostino DE. Pediatric end-stage liver disease score in acute liver failure to assess poor prognosis. J Pediatr Gastroenterol Nutr, 2012, 54(2):193-196.